Erythromycin hydrochloride

• CAT Number: I026998
• CAS Number: 14271-02-4
• Molecular Formula: C37H68ClNO13
• Molecular Weight: 770.39
• Purity: 98%
• Synonyms: Erythromycin hydrochloride; Erythromycin HCl; Ilotycin hydrochloride; Ilotycin HCl
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione hydrochloride
• InChI: 1S/C37H67NO13.ClH/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;1H/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;/m1./s1
• InChIKey: BXBSPTIDIMGJNO-YZPBMOCRSA-N
• SMILES: Cl.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

Erythromycin hydrochloride (Cat No.: I026998) is a macrolide antibiotic derived from Streptomyces erythraea, used to treat a variety of bacterial infections. It works by inhibiting protein synthesis through binding to the 50S ribosomal subunit, effectively stopping bacterial growth. The hydrochloride salt form enhances its solubility and stability for oral or injectable formulations. Erythromycin is commonly prescribed for respiratory tract infections, skin infections, and sexually transmitted diseases. It is also used for patients allergic to penicillin and has prokinetic effects on gastrointestinal motility.

Reference

1: Krasniqi S, Matzneller P, Kinzig M, Sörgel F, Hüttner S, Lackner E, Müller M, Zeitlinger M. Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy. Antimicrob Agents Chemother. 2012 Feb;56(2):1059-64. doi: 10.1128/AAC.05490-11. Epub 2011 Nov 14. PubMed PMID: 22083477; PubMed Central PMCID: PMC3264267.
2: Liang JH, Han X. Structure-activity relationships and mechanism of action of macrolides derived from erythromycin as antibacterial agents. Curr Top Med Chem. 2013;13(24):3131-64. Review. PubMed PMID: 24200358.
3: Li X, Ma S, Yan M, Wang Y, Ma S. Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. Eur J Med Chem. 2013 Jan;59:209-17. doi: 10.1016/j.ejmech.2012.11.028. Epub 2012 Nov 24. PubMed PMID: 23229056.
4: Vendrell D, Serarols L, Balcázar JL, de Blas I, Gironés O, Múzquiz JL, Ruiz-Zarzuela I. Accumulation and depletion kinetics of erythromycin in rainbow trout (Oncorhynchus mykiss). Prev Vet Med. 2012 Jun 1;105(1-2):160-3. doi: 10.1016/j.prevetmed.2012.02.017. Epub 2012 Mar 20. PubMed PMID: 22436556.
5: Carreras C, Frykman S, Ou S, Cadapan L, Zavala S, Woo E, Leaf T, Carney J, Burlingame M, Patel S, Ashley G, Licari P. Saccharopolyspora erythraea-catalyzed bioconversion of 6-deoxyerythronolide B analogs for production of novel erythromycins. J Biotechnol. 2002 Jan 18;92(3):217-28. PubMed PMID: 11689246.